Novel Approaches for the Treatment of Drug-Resistant Tuberculosis
Sonam Pushkar1★, Vibhav Varshney2, Pushpendra Pushkar3, Harish Kumar Sagar4★ Corresponding author
- 1Department of Pharmacy, GSVM Medical College, Kanpur, Uttar Pradesh, INDIA.
- 2Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, INDIA.
- 3Department of Pharmacology, GSVM Medical College, Kanpur, Uttar Pradesh, INDIA.
- 4ICMR National JALMA Institute for Leprosy and Other Mycobacterial Diseases, Agra, Uttar Pradesh, INDIA.
CORRESPONDENCE
Sonam Pushkar
Department of Pharmacy, GSVM Medical College, Kanpur, Uttar Pradesh, INDIA.
Received: 24-11-2022; Revised: 28-12-2022; Accepted: 11-01-2023.
Volume 15, Issue 2 · pp. 235–241 · PUBLISHED · DOI: 10.5530/pres.15.2.025
View on Pharmacogn. Res. original site ↗
ABSTRACT
Tuberculosis (TB) is a leading infectious disease that caused the deaths of a total of 1.5 million people in 2020 and is one of the top causes of death globally. India is a country with the highest TB burden, and it may affect all age groups. It is caused by the Mycobacterium tuberculosis bacteria, an intracellular pathogen, and its multidrug and extensively drug-resistant strains, which continue to emerge and spread, resulting in the deadliest infectious disease. After a gap of more than 40 years, the FDA approvals over the past decade of three second-line anti-TB drugs, bedaquiline, delamanid, and pretomanid, have been major forward steps in the management of drug-resistant-TB (DR-TB). Many medicinal plants such as Zanthoxylum leprieurii, Lantana camara, and Cryptolepis sanguinolenta have extensive therapeutic potential and represent a prospective option to fight against DR-TB. Some novel compounds are in the early clinical trial phases such as DprE1 inhibitors TBA-7371 and BTZ-043, and many others that are showing promising futures. This review describes DR-TB and its current chemotherapy guidelines including novel and repurposed drugs that are included in the anti-TB regimens, medicinal plants that have therapeutic potential for the development of drug-hit candidates, drugs that are currently in clinical development, host-directed therapy, and new drug delivery systems to better understand the novel therapeutic approaches that are currently being studied for the efficacious and safe management of DR-TB, a worldwide health problem.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Pushkar, S., Varshney, V., Pushkar, P., & Sagar, H. K. (). Novel Approaches for the Treatment of Drug-Resistant Tuberculosis. Pharmacognosy Research, 15(2), 235–241. https://doi.org/10.5530/pres.15.2.025